Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2024 · 65 positions · Total reported value $1.13B · Top-10 concentration 64.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2024 13F filing, Eversept Partners, LP disclosed 65 equity positions with a combined reported value of $1.13B. The filing implies a focused portfolio: its ten largest positions account for 64.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were NTRA ($138.79M), QQQ ($124.28M), GSK ($123.84M). By sector, the heaviest allocations are Health Care 73.0%, Industrials 5.9%. Versus the prior quarter, allocation shifted toward Other (+2.8pp), Consumer Discretionary (+1.5pp) and away from Health Care (-5.0pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q4 2024 were TLT ($15.67M), BRKR ($13.77M), EW ($12.64M).

Of the 27 positions fully exited versus the prior quarter, the largest were INSM ($79.53M), BHC ($12.49M), ITCI ($9.11M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • TLT ISHARES TR · $15.67M
  • BRKR BRUKER CORP · $13.77M
  • EW EDWARDS LIFESCIENCES CORP · $12.64M
  • DXCM DEXCOM INC · $11.56M
  • TFX TELEFLEX INCORPORATED · $10.99M
  • PCVX VAXCYTE INC · $10.44M
  • GH GUARDANT HEALTH INC · $8.43M
  • AZN ASTRAZENECA PLC · $6.73M

Fully Exited (vs previous quarter)

  • INSM INSMED INC · prev qtr: $79.53M · history
  • BHC BAUSCH HEALTH COS INC · prev qtr: $12.49M
  • ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $9.11M
  • BHVN BIOHAVEN LTD · prev qtr: $6.62M
  • BKD BROOKDALE SR LIVING INC · prev qtr: $5.85M · history
  • FNA PARAGON 28 INC · prev qtr: $5.00M
  • KURA KURA ONCOLOGY INC · prev qtr: $3.76M
  • MOH MOLINA HEALTHCARE INC · prev qtr: $3.65M · history

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 73.0%
Other 17.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 876.77K $138.79M 12.32%
12.32%
Add
2 243.10K $124.28M 11.03%
11.03%
Reduce
3 3.66M $123.84M 10.99%
10.99%
Reduce
4 1.60M $67.66M 6.01%
6.01%
Reduce
5 294.30K $54.56M 4.84%
4.84%
Add
6 175.81K $52.77M 4.68%
4.68%
Add
7 2.24M $49.42M 4.39%
4.39%
Reduce
8 392.52K $43.81M 3.89%
3.89%
Reduce
9 386.70K $37.10M 3.29%
3.29%
Add
10 2.07M $28.89M 2.56%
2.56%
Hold
11 678.79K $26.20M 2.33%
2.33%
Add
12 299.31K $21.56M 1.91%
1.91%
Reduce
13 719.84K $18.19M 1.61%
1.61%
Add
14 29.80K $17.47M 1.55%
1.55%
Reduce
15 1.27M $15.84M 1.41%
1.41%
Reduce
16 179.40K $15.67M 1.39%
1.39%
New
17 43.70K $15.42M 1.37%
1.37%
Reduce
18 780.00K $14.95M 1.33%
1.33%
Add
19 1.98M $14.89M 1.32%
1.32%
Add
20 234.93K $13.77M 1.22%
1.22%
New
21 170.68K $12.64M 1.12%
1.12%
New
22 148.69K $11.56M 1.03%
1.03%
New
23 188.49K $11.42M 1.01%
1.01%
Add
24 61.74K $10.99M 0.97%
0.97%
New
25 29.18K $10.76M 0.96%
0.96%
Add
26 127.59K $10.44M 0.93%
0.93%
New
27 490.30K $8.54M 0.76%
0.76%
Reduce
28 2.83M $8.45M 0.75%
0.75%
Reduce
29 276.04K $8.43M 0.75%
0.75%
New
30 54.07K $7.78M 0.69%
0.69%
Reduce
31 214.95K $7.51M 0.67%
0.67%
Reduce
32 401.73K $7.49M 0.67%
0.67%
Reduce
33 275.36K $7.08M 0.63%
0.63%
Reduce
34 102.66K $6.73M 0.60%
0.60%
New
35 571.30K $6.72M 0.60%
0.60%
Add
36 19.05K $6.33M 0.56%
0.56%
New
37 155.54K $6.10M 0.54%
0.54%
New
38 911.02K $5.86M 0.52%
0.52%
Reduce
39 22.68K $5.75M 0.51%
0.51%
Reduce
40 80.30K $5.56M 0.49%
0.49%
New
41 22.21K $5.10M 0.45%
0.45%
Reduce
42 343.40K $4.54M 0.40%
0.40%
Reduce
43 146.05K $4.51M 0.40%
0.40%
New
44 4.98M $4.50M 0.40%
0.40%
Hold
45 383.05K $4.23M 0.38%
0.38%
Reduce
46 19.25K $4.04M 0.36%
0.36%
Add
47 105.58K $3.82M 0.34%
0.34%
New
48 168.37K $3.55M 0.32%
0.32%
Hold
49 996.10K $3.04M 0.27%
0.27%
Reduce
50 1.00M $2.95M 0.26%
0.26%
Add

FAQ

What did Eversept Partners, LP buy in 2024-Q4?

In its 2024-Q4 13F filing, Eversept Partners, LP reported 65 equity positions worth $1.13B in aggregate; its largest disclosed positions were NTRA ($138.79M), QQQ ($124.28M), GSK ($123.84M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.13B of long equity holdings across 65 positions as of 2024-Q4. Top-10 holdings account for 64.0% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →